Brenus Pharma, a Lyon, France-based biotech company specializing in the development of cancer vaccines, raised $25M in Series A Funding.
The round was led by Angelor, with participation from UI Investissement, Crédit Agricole Centre-France and Crédit Agricole Centre-Est, with 2 family offices. Belgian funds Noshaq and Investsud completed this deal. Together, they joined co-founder and lead investor Jacques Gardette (BIOJAG) and long-time investor Stéphane Legastelois (33 CALIFORNIE). In addition, Brenus Pharma has received non-dilutive funding from the French government and Bpifrance, as beneficiary of the France 2030 call for projects.
The company intends to use the funds to finance the first Phase I/IIA clinical trial of its first candidate, STC-1010, in metastatic colorectal cancer, as well as the development of a second candidate in another solid tumor indication (STC-1020).
Led by CEO Paul Bravetti, Brenus Pharma develops its proteomics-guided allogeneic cancer vaccines, generated by the patented STC ‘Stimulated-Tumor-(ghost)-Cell’ platform for the treatment of solid tumors. STC mimics the relapse conditions of patients’ tumor cells to educate their immune systems to be able to anticipate, target and destroy these tumor cells as soon as they appear.
STC-1010 is a vaccine candidate based on the STC ‘Stimulated-Tumor-(ghost)-Cells’ technology platform developed by Brenus Pharma.
FinSMEs
18/09/2024